Cargando…

The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study

BACKGROUND: Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Bertolo, Riccardo, Cipriani, Chiara, Vittori, Matteo, Carilli, Marco, Maiorino, Francesco, Iacovelli, Valerio, Ganini, Carlo, Antonucci, Michele, Signoretti, Marta, Petta, Filomena, Panei, Massimo, Bove, Pierluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840549/
https://www.ncbi.nlm.nih.gov/pubmed/35151280
http://dx.doi.org/10.1186/s12894-022-00974-0
_version_ 1784650647873781760
author Bertolo, Riccardo
Cipriani, Chiara
Vittori, Matteo
Carilli, Marco
Maiorino, Francesco
Iacovelli, Valerio
Ganini, Carlo
Antonucci, Michele
Signoretti, Marta
Petta, Filomena
Panei, Massimo
Bove, Pierluigi
author_facet Bertolo, Riccardo
Cipriani, Chiara
Vittori, Matteo
Carilli, Marco
Maiorino, Francesco
Iacovelli, Valerio
Ganini, Carlo
Antonucci, Michele
Signoretti, Marta
Petta, Filomena
Panei, Massimo
Bove, Pierluigi
author_sort Bertolo, Riccardo
collection PubMed
description BACKGROUND: Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). METHODS: In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. RESULTS: 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. CONCLUSIONS: The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively. TRIAL REGISTRATION: The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918.
format Online
Article
Text
id pubmed-8840549
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88405492022-02-16 The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study Bertolo, Riccardo Cipriani, Chiara Vittori, Matteo Carilli, Marco Maiorino, Francesco Iacovelli, Valerio Ganini, Carlo Antonucci, Michele Signoretti, Marta Petta, Filomena Panei, Massimo Bove, Pierluigi BMC Urol Research BACKGROUND: Several studies described post-operative irritative symptoms after laser enucleation of prostate, sometimes associated with urge incontinence, probably linked to laser-induced prostatic capsule irritation, and potential for lower urinary tract infections We aimed to evaluate the efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate (ThuLEP). METHODS: In this single-center, prospective, randomized, open label, phase-III study, patients with indication to ThuLEP were enrolled (Dec2019–Feb2021—Institutional ethics committee STS CE Lazio approval no.1/N-726—ClinicalTrials.gov NCT05130918). The report conformed to CONSORT 2010 guidelines. Eligible patients were 1:1 randomized. Randomization defined Group A: patients who were administered Mictalase® suppositories twice a day for 5 days, then once a day for other 10 days; Group B: patients who did not receive Mictalase® (“controls”). Study endpoints were evaluated at 15 and 30 days postoperation. Primary endpoint included evaluation of effects of the suppository on irritative symptoms by administering IPSS + QoL questionnaire. Secondary endpoint included evaluation of effects on urinary tract infections by performance of urinalysis with urine culture. RESULTS: 111 patients were randomized: 56 in Group A received Mictalase®. Baseline and perioperative data were comparable. At 15-days, no significant differences were found in terms of IPSS + QoL scores and urinalysis parameters. A significant difference in the rate of positive urine cultures favored Group A (p = 0.04). At 30-days follow-up, significant differences were found in median IPSS score (6 [IQR 3–11] versus 10 [5–13], Group A vs B, respectively, p = 0.02). Urinalysis parameters and rate of positive urine cultures were not significantly different. CONCLUSIONS: The present randomized trial investigated the efficacy of Mictalase® in control of irritative symptoms and prevention of lower urinary tract infections in patients undergoing ThuLEP. IPSS improvement 30-days postoperation was more pronounced in patients who received Mictalase®. Lower rate of positive urine culture favored Mictalase® group 15-days postoperatively. TRIAL REGISTRATION: The clinical trial has been registered on ClinicalTrials.gov on November 23rd, 2021—Registration number NCT05130918. BioMed Central 2022-02-12 /pmc/articles/PMC8840549/ /pubmed/35151280 http://dx.doi.org/10.1186/s12894-022-00974-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bertolo, Riccardo
Cipriani, Chiara
Vittori, Matteo
Carilli, Marco
Maiorino, Francesco
Iacovelli, Valerio
Ganini, Carlo
Antonucci, Michele
Signoretti, Marta
Petta, Filomena
Panei, Massimo
Bove, Pierluigi
The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title_full The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title_fullStr The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title_full_unstemmed The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title_short The efficacy of a suppository based on Phenolmicin P3 and Bosexil (Mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase III study
title_sort efficacy of a suppository based on phenolmicin p3 and bosexil (mictalase®) in control of irritative symptoms in patients undergoing thulium laser enucleation of prostate: a single-center, randomized, controlled, open label, phase iii study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8840549/
https://www.ncbi.nlm.nih.gov/pubmed/35151280
http://dx.doi.org/10.1186/s12894-022-00974-0
work_keys_str_mv AT bertoloriccardo theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT ciprianichiara theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT vittorimatteo theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT carillimarco theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT maiorinofrancesco theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT iacovellivalerio theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT ganinicarlo theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT antonuccimichele theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT signorettimarta theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT pettafilomena theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT paneimassimo theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT bovepierluigi theefficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT bertoloriccardo efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT ciprianichiara efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT vittorimatteo efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT carillimarco efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT maiorinofrancesco efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT iacovellivalerio efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT ganinicarlo efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT antonuccimichele efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT signorettimarta efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT pettafilomena efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT paneimassimo efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy
AT bovepierluigi efficacyofasuppositorybasedonphenolmicinp3andbosexilmictalaseincontrolofirritativesymptomsinpatientsundergoingthuliumlaserenucleationofprostateasinglecenterrandomizedcontrolledopenlabelphaseiiistudy